Walnut-Derived Peptide FDWLR Lowers Blood Pressure in Hypertensive Rats and Protects Blood Vessels
A novel walnut peptide (FDWLR, IC50 8.02 μg/mL) potently inhibited ACE, protected blood vessel cells from angiotensin II damage, and significantly lowered blood pressure in spontaneously hypertensive rats.
Quick Facts
What This Study Found
FDWLR from walnut protein (IC50 8.02 μg/mL ACE inhibition) demonstrated triple validation: in vitro ACE blocking, HUVEC vasoprotection against angiotensin II, and in vivo blood pressure lowering in spontaneously hypertensive rats.
Key Numbers
Most potent peptide identified from walnut hydrolysate. Validated through in vitro ACE inhibition, HUVEC protection, and blood pressure reduction in SHR rats.
How They Did This
Walnut protein hydrolyzed by alcalase + simulated GI digestion. Peptides separated by Sephadex-G25, identified by peptidomics, screened via PeptideRanker and in silico analysis. Validated by ACE inhibition assay, molecular docking, ADMET prediction, HUVEC angiotensin II challenge, and oral administration to SHR.
Why This Research Matters
Walnuts have long been associated with heart health, but this study identifies a specific peptide responsible and proves it works through multiple validated experiments — moving beyond epidemiological associations to molecular-level evidence.
The Bigger Picture
This adds walnuts to the growing list of foods (alongside milk, garlic, fish, and soy) with identified, validated ACE-inhibitory peptides. The comprehensive characterization of FDWLR — from discovery through in vivo validation — provides a template for functional food peptide development.
What This Study Doesn't Tell Us
Animal study using spontaneously hypertensive rats. The human dose needed for blood pressure effects is unknown. In silico ADMET predictions need confirmation with actual pharmacokinetic studies. Long-term safety data is lacking.
Questions This Raises
- ?How much walnut consumption would be needed to deliver a meaningful dose of FDWLR?
- ?Does FDWLR survive actual human digestion as predicted by the simulation?
- ?Would FDWLR be effective in human patients with essential hypertension?
Trust & Context
- Key Stat:
- IC50 8.02 μg/mL FDWLR from walnut protein is exceptionally potent for a food-derived ACE inhibitor, with confirmed blood pressure lowering in hypertensive rats
- Evidence Grade:
- Moderate evidence combining in vitro ACE inhibition, computational analysis, cell culture validation, and in vivo animal testing. Human clinical trials have not been conducted.
- Study Age:
- Published in 2024; represents current food-derived antihypertensive peptide research.
- Original Title:
- A novel angiotensin I-converting enzyme inhibitory peptide from walnut (Juglans sigillata) protein hydrolysates and its evaluation in Ang II-induced HUVECs and hypertensive rats.
- Published In:
- International journal of biological macromolecules, 266(Pt 2), 131152 (2024)
- Authors:
- Xie, Jinxiang, Chen, Shupeng(2), Huan, Pengtao(2), Wang, Shuguang, Zhuang, Yongliang
- Database ID:
- RPEP-09561
Evidence Hierarchy
Frequently Asked Questions
Are walnuts good for blood pressure?
Clinical studies have shown that regular walnut consumption is associated with modest cardiovascular benefits. This study identifies a specific peptide (FDWLR) that blocks the blood-pressure-raising enzyme ACE, providing a molecular explanation for these observed benefits.
Can I get this peptide from eating walnuts?
The peptide FDWLR was released when walnut protein was broken down by digestive enzymes, suggesting it could be generated during normal digestion. However, the amount released and absorbed from eating walnuts versus the concentrated doses used in the study isn't known.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09561APA
Xie, Jinxiang; Chen, Shupeng; Huan, Pengtao; Wang, Shuguang; Zhuang, Yongliang. (2024). A novel angiotensin I-converting enzyme inhibitory peptide from walnut (Juglans sigillata) protein hydrolysates and its evaluation in Ang II-induced HUVECs and hypertensive rats.. International journal of biological macromolecules, 266(Pt 2), 131152. https://doi.org/10.1016/j.ijbiomac.2024.131152
MLA
Xie, Jinxiang, et al. "A novel angiotensin I-converting enzyme inhibitory peptide from walnut (Juglans sigillata) protein hydrolysates and its evaluation in Ang II-induced HUVECs and hypertensive rats.." International journal of biological macromolecules, 2024. https://doi.org/10.1016/j.ijbiomac.2024.131152
RethinkPeptides
RethinkPeptides Research Database. "A novel angiotensin I-converting enzyme inhibitory peptide f..." RPEP-09561. Retrieved from https://rethinkpeptides.com/research/xie-2024-a-novel-angiotensin-iconverting
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.